Your browser doesn't support javascript.
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
S, Sugin Lal Jabaris; V, Ranju.
  • S SLJ; Department of Pharmacology, Siddha Central Research Institute, Central Council for Research in Siddha, Ministry of AYUSH, Govt. of India, Anna Hospital Campus, Arumbakkam, Chennai-106, India. Electronic address: lalpharm78@gmail.com.
  • V R; Department of Genetic Toxicology, Microbiology and In Vitro Toxicology, Eurofins Advinus, Phase 21 & 22, Bangalore-560 058, India.
Pulm Pharmacol Ther ; 66: 101978, 2021 02.
Article in English | MEDLINE | ID: covidwho-947382
ABSTRACT
The recent pandemic of COVID-19 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an extraordinary challenge to identify effective drugs for prevention and treatment. The pathogenesis implicate acute respiratory disorder (ARD) which is attributed to significantly triggered "cytokine storm" and compromised immune system. This article summarizes the likely benefits of roflumilast, a Phosphodiesterase-4 (PDE-4) inhibitor as a comprehensive support COVID-19 pathogenesis. Roflumilast, a well-known anti-inflammatory and immunomodulatory drug, is protective against respiratory models of chemical and smoke induced lung damage. There is significant data which demonstrate the protective effect of PDE-4 inhibitor in respiratory viral models and is likely to be beneficial in combating COVID-19 pathogenesis. Roflumilast is effective in patients with severe COPD by reducing the rate of exacerbations with the improvement of the lung function, which might further be beneficial for better clinical outcomes in COVID-19 patients. However, further clinical trials are warranted to examine this conjecture.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzamides / Phosphodiesterase 4 Inhibitors / COVID-19 Drug Treatment / Aminopyridines / Anti-Inflammatory Agents Type of study: Prognostic study Language: English Journal: Pulm Pharmacol Ther Journal subject: Pharmacology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Benzamides / Phosphodiesterase 4 Inhibitors / COVID-19 Drug Treatment / Aminopyridines / Anti-Inflammatory Agents Type of study: Prognostic study Language: English Journal: Pulm Pharmacol Ther Journal subject: Pharmacology Year: 2021 Document Type: Article